Jonathan Peacock Net Worth

The estimated Net Worth of Jonathan M Peacock is at least $50.8 Million dollars as of 21 May 2019. Mr. Peacock owns over 20,000 units of Avantor stock worth over $50,481,007 and over the last 14 years he sold AVTR stock worth over $0. In addition, he makes $292,504 as Independent Director at Avantor.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Peacock AVTR stock SEC Form 4 insiders trading

Jonathan has made over 8 trades of the Avantor stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of AVTR stock worth $12,200 on 21 May 2019.

The largest trade he's ever made was buying 714,286 units of Avantor stock on 25 January 2019 worth over $500,000. On average, Jonathan trades about 21,512 units every 42 days since 2010. As of 21 May 2019 he still owns at least 1,875,920 units of Avantor stock.

You can see the complete history of Mr. Peacock stock trades at the bottom of the page.

Jonathan Peacock biography

Jonathan Peacock is Independent Director of the company. Mr. Peacock has served on our Board since 2017 and currently is the Chair of the Audit and Finance Committee and a member of the Nominating and Governance Committee. Mr. Peacock has been the Chairman of Arix Bioscience PLC, a global health and life sciences specialist investor in medical innovation, since 2016. From June 2014 to November 2016, Mr. Peacock served as the Chairman and Chief Executive Officer of Bellerophon Therapeutics, Inc., a clinical stage biotherapeutics company, and has served as Chairman since 2016. Prior to that time, Mr. Peacock served as the Chief Financial Officer of Amgen Inc, a biopharmaceutical company, from September 2010 to January 2014. Mr. Peacock was the Chief Financial and Administrative Officer of the Pharmaceuticals Division of Novartis AG, a global healthcare company, from November 2005 to September 2010. Mr. Peacock also serves as a director of Genmab A/S, where he is a member of the Audit and Finance Committee and the Compensation Committee. In the past five years, Mr. Peacock served as a director of Kite Pharma where he was the chair of the Audit and Finance Committee. Mr. Peacock earned a M.A. in Economics from the University of St. Andrews in Scotland and is a Chartered Accountant.

What is the salary of Jonathan Peacock?

As the Independent Director of Avantor, the total compensation of Jonathan Peacock at Avantor is $292,504. There are 11 executives at Avantor getting paid more, with Michael Stubblefield having the highest compensation of $16,995,300.

How old is Jonathan Peacock?

Jonathan Peacock is 62, he's been the Independent Director of Avantor since 2017. There are 3 older and 28 younger executives at Avantor. The oldest executive at Avantor Inc. is Rajiv Gupta, 74, who is the Chairman of the Board.

What's Jonathan Peacock's mailing address?

Jonathan's mailing address filed with the SEC is RADNOR CORPORATE CENTER, BUILDING ONE,, SUITE 200, 100 MATSONFORD ROAD, RADNOR, PA, 19087.

Insiders trading at Avantor

Over the last 5 years, insiders at Avantor have traded over $3,149,576,044 worth of Avantor stock and bought 27,800 units worth $584,024 . The most active insiders traders include Mountain Investments Iii, L..., Jo Natauri, and Sachs & Co. Llc Stone Bridg.... On average, Avantor executives and independent directors trade stock every 21 days with the average trade being worth of $48,107,115. The most recent stock trade was executed by Steven W Eck on 5 September 2024, trading 3,525 units of AVTR stock currently worth $88,337.

What does Avantor do?

based in center valley, pa (usa), avantor performance materials manufactures and markets high-performance chemistries and materials around the world under several respected brand names, including the j.t.baker®, macron fine chemicals™, rankem™, benesphera™, and poch™ brands. avantor products are used in a wide range of industries. our life sciences solutions are used in pharmaceutical production, laboratory research for academic, industry and quality control, and in medical lab testing. our electronics solutions are used in the manufacturing of semiconductors. for additional information please visit www.avantormaterials.com

Complete history of Mr. Peacock stock trades at AMGEN, Bellerophon Therapeutics Inc, and Avantor

Avantor executives and stock owners

Avantor executives and other stock owners filed with the SEC include:

• Michael Stubblefield,
  President, Chief Executive Officer, Director
• Thomas Szlosek,
  Chief Financial Officer, Executive Vice President
• Michael Stubblefield,
  Pres, CEO & Director
• Gerard Brophy,
  Executive Vice President - Biopharma Production
• Devashish Ohri,
  Executive Vice President - AMEA
• Frederic Vanderhaegen,
  Executive Vice President - Americas and Europe
• Thomas A. Szlosek,
  Exec. VP & CFO
• Frederic Vanderhaegen,
  Exec. VP of Americas & Europe
• Dr. Gerald Brophy Ph.D.,
  Exec. VP of Biopharma Production
• Michael Wondrasch,
  Exec. VP & Chief Information Officer
• Rajiv Gupta,
  Chairman of the Board
• Jonathan Peacock,
  Independent Director
• Christi Shaw,
  Independent Director
• Rakesh Sachdev,
  Independent Director
• Juan Andres,
  Independent Director
• Gregory Summe,
  Independent Director
• Michael Severino,
  Independent Director
• Jo Natauri,
  Director
• Andre Moura,
  Director
• Matthew Holt,
  Director
• Steven Eck,
  Senior Vice President, Chief Accounting Officer
• Mark Murray,
  Executive Vice President of the Biomaterials and Advanced Technologies Platform
• Sven Henrichwark,
  Executive Vice President of APAC
• Tanya Foxe,
  Executive Vice President - Global Operations and Supply Chain
• Christophe Couturier,
  Executive Vice President - Services, Strategy and Business Transformation
• James Bramwell,
  Executive Vice President - Strategic Partners
• Justin Miller,
  Executive Vice President, General Counsel, Secretary
• Michael Wondrasch,
  Executive Vice President, Chief Information Officer
• Eric McAllister,
  Chief Human Resource Officer, Executive Vice President
• Allison K. Hosak,
  Sr. VP of Global Communications & Brand
• Justin M. Miller Esq.,
  Exec. VP, Gen. Counsel & Sec.
• Tommy J. Thomas CPA,
  VP of Investor Relations
• Steven W. Eck,
  Sr. VP, Corp. Controller & Chief Accounting Officer
• Sheri Lewis,
  Exec. VP, Global Operations & Supply Chain
• Lan Kang,
  Director
• John Carethers,
  Director
• Sachs & Co. Llc Stone Bridg...,
  
• Sachs & Co. Llc Stone Bridg...,
  
• Sheri Lewis,
  EVP, Global Ops & Supply Chain
• Mountain Investments Iii, L...,
  
• Mala Murthy,
  Director
• Brittany Hankamer,
  EVP, Chief HR Officer
• Randy Lee Stone,
  EVP, Laboratory Solutions
• Corey Walker,
  President Laboratory Solutions
• Ashish Kulkarni,
  See Remarks
• Sachs & Co. Llcgoldman Sach...,
  
• Meghan Henson,
  EVP, Chief HR Officer
• Thomas Connolly,
  Director
• Joseph R Massaro,
  Director
• Kitty Sahin,
  EVP, Strategy&Corp Development
• Claudius Sokenu,
  EVP, Chief Legal & Compliance
• R. Brent Jones,
  EVP, Chief Financial Officer
• Benoit Gourdier,
  EVP, Biopharma Production